Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Neoplasms 1Chromosome 17 deletion 1Blast Crisis 1Amyloidosis 1

Interventions

ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1RG7388 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Chromosome 17 deletion × dexamethasone 21-phosphate × Clear all
NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
33 enrolled 26 charts
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡